Message from Top Management

Shionogi traces its roots back to 1878, when it was founded as Shiono Gisaburo Shoten, a drug wholesaler.

Since then, the pharmaceutical market and society have both evolved considerably, and Shionogi has grown by adapting its business in line with the changing times.

However, over the past 140 years, one thing has not changed – our steadfast commitment to develop even better medicines, and to provide clear, accurate, and appropriate guidance for their proper use to healthcare professionals and patients.

Even when business conditions have been tough, we have worked through the challenges without straying from our Company Policy: “Shionogi strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve.”

 

That long-held policy is firmly entrenched in our organization as Shionogi’s philosophy, supporting our growth through the years.

SHIONOGI stated the goals it wants to achieve by 2030, as SHIONOGI Group Vision (2030 Vision): “Building Innovation Platforms to Shape the Future of Healthcare”. We will continue to build upon our established capabilities as a drug discovery-based pharmaceutical company based on innovation and highly advanced expertise, while increasingly catalyzing the formation of new healthcare platforms as the partner of choice for companies and industries with complementary capabilities and expertise in other fields.

In order to create new value by addressing the problems faced by patients and society more thoroughly, Shionogi will evolve from a pharmaceutical company whose primary role is to provide prescription drug to a HaaS* company that offers increasingly comprehensive healthcare services.

*Healthcare as a Service: Provide a range of healthcare services in line with customer needs, rather than only providing pharmaceuticals.

In June 2020, we hasformulated and launched the Medium-Term Business Plan “STS2030”, aiming to realize our vision for 2030（our 2030 Vision）. In the three fiscal years since we formulated STS2030, the external environment surrounding the healthcare sector has changed even more rapidly than we expected. The entire world underwent the social and medical turmoil caused by the COVID-19 (SARS-CoV-2) pandemic, struggled to contain the spread of the virus, reconsidered approaches to ensuring citizen safety, and reaffirmed the importance of people’s health in maintaining a functional society.

Under this rapidly changing environment, SHIONOGI has evolved its drug discovery capabilities and developed a COVID-19 therapeutic drug. In addition, building upon our foundations as a company, we have been working to to expand our range of products and services beyond prescription drugs. For example, we have developed our first vaccine and established a wastewater epidemiological surveillance service.

Our direction we remain unchanged from when we originally formulated STS2030, but the efforts we have made and the lessons we have learned over the past three fiscal years have made the path toward achieving our 2030 Vision even clearer, and we therefore decided to revise STS2030 and to reformulate it into the STS2030 Revision.

In the STS2030 Revision, we strives constantly to supply the best possible medicine (healthcare solutions)' globally, with three pillars of growth: HIV business, COVID-19 treatment, and new products/new businesses. By doing so, we will solve social issues, achieve sustainable growth together with society, and aim to achieve our 2030 Vision.

I would like to thank you for your interest in our company and our products and your continued support will be greatly appreciated.